Ainos Q1 revenue up 412% to $106K; gross profit swings to positive; partnerships in robotics and semiconductors

Ainos, Inc.

2025-Q1 EPS reported -$0.21 revenue$106,207

Revenue up 412% YoY to $106,207; gross profit of $87,974 vs prior-year gross loss of $6,025.
Cost of revenue down 32% YoY to $18,233, driving gross margin improvement.
AI Nose deployed in semiconductor manufacturing via ASE partnership; olfactory module installed on ugo robots.
VELDONA secured TFDA approval for HIV oral warts trial and IRB clearance for Sjögren's syndrome trial.
No net income or EPS disclosed; share-based compensation increased SG&A expenses.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.